

# Subject Index

- Age-related macular degeneration, photoreceptor death 125
- Allergy
  - epidemiology and trends in children 155, 156
  - n-3 fatty acid supplementation
    - in prevention
    - epidemiological studies 157
    - intervention studies
      - clinical implications 160
      - maternal supplementation studies 158, 159
      - postnatal period 159, 160
      - rationale 156, 157
- Antibiotic-associated diarrhea, probiotics in prevention 101
- Arginine
  - asthma dysregulation
    - arginase role 4–8
    - metabolome therapeutic targeting 10, 11
    - nitric oxide synthase
      - endogenous inhibitors 9, 10
      - uncoupling 8, 9
    - overview 3–5
    - uptake 8
  - metabolism 18, 19
  - pediatric sepsis and critical illness studies
    - deficiency 23, 24
    - kinetic analysis 21–23
    - nitric oxide synthesis 23, 25
    - plasma concentration 19–21
    - supplementation studies 25, 26
  - preterm infant supplementation 52
  - trauma and surgery infection studies
    - arginase expression in immature myeloid cells 36, 37
    - arginine replacement therapy
      - clinical benefits 41–43
      - nitric oxide production response 39, 40
      - T cell function 40, 41
    - diagnosis of arginine deficiency 38, 39
    - myeloid cells and arginine metabolism 33–36
    - overview 29, 30
    - plasma level reduction response 32, 33
    - public health implications 31
    - T cell dysfunction 37, 38
- Asthma
  - arginine dysregulation
    - arginase role 4–8
    - metabolome therapeutic targeting 10, 11
    - nitric oxide synthase
      - endogenous inhibitors 9, 10
      - uncoupling 8, 9
    - overview 3–5
    - uptake 8
  - diagnosis 2
  - epidemiology 1, 2
  - nitric oxide dysregulation 2, 3

- Asymmetrical dimethylarginine
  - asthma levels 9
  - pediatric sepsis and critical illness levels 25
- Bayley Scales of Infant Development 148
- Bifidobacteria, *see* Probiotics
- Branched-chain fatty acids
  - dietary intake 140–142
  - enterocyte metabolism 134–137
  - necrotizing enterocolitis studies 137–140
  - neonatal gut function 134, 135, 138
  - overview 133, 134, 169
- Breastfeeding
  - advantages 27, 28
  - hormones and growth factors in milk 58, 165
  - insulin
    - diabetes protection 61
    - gut maturation role 59, 60
    - milk content 59
    - systemic effects 61
- Cationic amino acid transporter
  - asthma studies 8
  - sepsis response 19
- Celiac disease, probiotic studies in children 107
- Choroidal neovascularization, neuroprotectin D1 inhibition 126
- Citrulline, plasma concentration in pediatric sepsis and critical illness 20, 23
- Colic, *see* Infantile colic
- C-reactive protein, plasma concentration in pediatric sepsis and critical illness 20, 22
- Critical illness, arginine studies in children
  - deficiency 23, 24
  - kinetic analysis 21–23
  - nitric oxide synthesis 23, 25
  - plasma concentration 19–21
  - supplementation studies 25, 26
- Crohn disease, *see* Inflammatory bowel disease
- CXCL8, probiotic induction 86
- Dendritic cell
  - arginine metabolism 33–37
  - intestine 93, 94
  - probiotic interactions 78
- Diabetes type 1, probiotic studies in children 107, 108
- DIAMOND study 148–150
- Diarrhea, probiotic studies
  - acute gastroenteritis 100, 101
  - antibiotic-associated diarrhea prevention 101
  - nosocomial diarrhea prevention 102, 103
- Docosahexaenoic acid, *see also* Fatty acids, dietary
  - allergy protection, *see* Allergy derivation 122–124
  - maternal supplementation studies 168, 169
  - neurodegeneration studies 124, 125
  - neuroprotectin D1 synthesis 123, 125
  - photoreceptor cell membrane composition and disease 125, 126
  - stroke studies 126, 127
- ELOVL, genetic variation and dietary fatty acid responses 117
- Enterotype, *see* Gut microbiota
- Epilepsy, docosahexaenoic acid and neuroprotectin D1 studies 127
- Fatty acid desaturase, genetic variation and dietary fatty acid responses 115, 116, 151, 152
- Fatty acids, dietary, *see also* Allergy, Branched-chain fatty acids, Docosahexaenoic acid
  - accumulation in fetus and infant 146
  - classification 112, 113
  - fatty acid desaturase polymorphisms and dietary requirements 151, 152
  - maternal-to-fetal transfer 150, 151
  - n-3/n-6 fatty acid responses
    - environmental factors 117, 118

- functional outcomes and cellular responses 113–115
- genetic variation and responses 115–117
- membrane composition and cellular responses 112, 113
- perinatal development effects of supplementation
  - developmental measure selection 147–149
  - timing of measurement of development 149, 150
- preterm infant supplementation 147
- Glutamine
  - functional overview 47, 48
  - preterm infant supplementation
    - challenges in study 53
    - critical illness studies 51
    - dipeptide therapy 52, 53
    - long-term follow-up studies 52
    - mechanisms of action 49–51
    - prospects for study 54
    - rationale 48, 49, 164, 165
- Gut microbiota, *see also* Probiotics
  - composition determinants 67, 68
  - diet impact 68, 69
  - disease association 66, 67
  - enterotypes, enterogradients, and disease 69, 70
  - immunomodulation
    - adaptive immunity 77
    - innate immunity 77
  - inflammatory bowel disease 67, 68, 71
  - overview 65, 66, 99, 100
- Human milk, *see* Breastfeeding
- Infant formula, insulin supplementation
  - preterm infant response 62, 63
  - safety 62
- Infantile colic, probiotic management 103, 104
- Inflammatory bowel disease
  - exclusive enteral nutrition therapy 96
  - gut microbiota 67, 68, 71
- transforming growth factor- $\beta$  role in Crohn disease 96
- Insulin
  - human milk
    - content 59, 165
    - diabetes protection 61
    - gut maturation role 59, 60
    - systemic effects 61
  - infant formula supplementation
    - preterm infant response 62, 63
    - safety 62
- Insulin-like growth factor-1, human milk 58
- Intestine
  - immune system overview 92–94
  - microbiota, *see* Gut microbiota
- Lactic acid bacteria, *see* Probiotics
- Microbiota, *see* Gut microbiota
- Necrotizing enterocolitis
  - branched-chain fatty acid studies 137–140
  - probiotics in prevention 104, 105
- Neuroprotectin D1
  - choroidal neovascularization inhibition 126
  - epilepsy studies 127
  - neurodegeneration studies 124, 125
  - photoreceptor cell membrane
    - composition and disease 125, 126
  - stroke studies 126, 127
  - synthesis 123, 125
- Nitric oxide
  - asthma studies
    - dysregulation 2, 3
    - nitric oxide synthase
      - endogenous inhibitors 9, 10
      - uncoupling 8, 9
  - nitric oxide synthase isoforms 18, 19
  - pediatric sepsis and critical illness studies 23, 25
  - trauma and surgery infection arginine replacement therapy and production response 39, 40

- n-3 fatty acids, *see* Allergy, Docosahexaenoic acid, Fatty acids, dietary
- Obesity, probiotic studies in children 106, 107
- Preterm infants
  - arginine supplementation 52
  - docosahexaenoic acid supplementation 147
  - glutamine supplementation
    - challenges in study 53
    - critical illness studies 51
    - dipeptide therapy 52, 53
    - long-term follow-up studies 52
    - mechanisms of action 49–51
    - prospects for study 54
    - rationale 48, 49
  - infant formula insulin supplementation 62, 63
- Probiotics, *see also* Gut microbiota immunomodulation
  - literature review 79–82
  - mechanisms 77–79, 86, 87
  - overview 76, 166, 167
- pediatric disease studies
  - acute gastroenteritis 100, 101
  - antibiotic-associated diarrhea prevention 101
  - celiac disease 107
  - diabetes type 1 studies 107, 108
  - infantile colic management 103, 104
  - necrotizing enterocolitis prevention 104, 105
  - nosocomial diarrhea prevention 102, 103
  - obesity 106, 107
  - respiratory tract infection prevention 105, 106
  - prospects for study 87, 88
  - screening for anti-inflammatory activity 82–87
- Respiratory tract infection, probiotics in prevention 105, 106
- Sepsis, arginine studies in children
  - deficiency 23, 24
  - kinetic analysis 21–23
  - nitric oxide synthesis 23, 25
  - plasma concentration 19–21
  - supplementation studies 25, 26
- Stearyl-CoA desaturase 1, genetic variation and dietary fatty acid responses 116
- Stroke, docosahexaenoic acid and neuroprotectin D1 studies 126, 127
- Surgery infection, *see* Arginine
- Symmetrical dimethylarginine, asthma levels 9
- Systemic inflammatory response syndrome, children 17, 18
- T cell
  - gut microbiota interactions 77–79
  - trauma and surgery infection studies
    - arginine replacement therapy response 40, 41
    - dysfunction 37, 38
- Transforming growth factor- $\beta$ 
  - Crohn disease role 96
  - intestine mucosa function 95, 96
  - signaling 94, 95
- Trauma, *see* Arginine
- Trimethylamine, gut microbiota synthesis 70
- Tumor necrosis factor- $\alpha$ , probiotic suppression 87